Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001.
Int Med Case Rep J
california; sjci; pni; covid-19
Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.
Neurosciences (Brain & Spine)
Hammond, Terese Catherine; Lee, Raymond C; Oronsky, Bryan; Reid, Tony R; Caroen, Scott; Juarez, Tiffany M; Gill, Jaya; Heng, Annie; and Kesari, Santosh, "Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001." (2022). Articles, Abstracts, and Reports. 6825.